earticle

논문검색

동물 및 식물세포공학 분야

Production and Purification of hGalT-CTLA4IgP in Transgenic Rice Cells

초록

영어

Human cytotoxic T-lymphocyte antigen 4-immunoglobulin (hCTLA4Ig), an immunosuppressive agent, is a glycoprotein and it was expressed in transgenic rice cell suspension cultures. As a production system, transgenic plant cells have several advantages including low risk of potential contamination with animal pathogens, economical large-scale production, and capacity to carry out most posttranslational modifications (PTMs). Among the PTMs, glycosylation is essential for proteins stability, folding and physiological activity.1, 2) However, there are differences in N-glycosylation between the glycoproteins produced in mammalian and plant cells. N-linked glycan structures contain penultimate galactose and terminal sialic acid residues in mammalian glycoproteins. In the case of plants, in vivo half-life of protein is decreased because of N-linked glycans with plant specific terminal β1, 3-galactose residues.3) To prolong the half-life of plant-made proteins, transgenic rice cells were transformed with human galactosyltransferase gene under the control of the RAmy3D promoter. Consequently, produced target proteins could have glycan structures with not only β1, 3-galactose but also β1, 4-galactose residues at the terminus. In this study, target proteins with terminal β1, 4-galactose oligosaccharides were purified by using Ricinus communis agglutinin (RCA120) lectins that binds to specific β1, 4-glactose structures. Through the purification process by RCA120 affinity chromatography, it was
confirmed that N-linked glycan structures of hCTLA4Ig was modified similar to that of
mammalian glycoproteins in transformed rice cells.

저자정보

  • Hye-Ran LEE Department of Biological Engineering, Inha University, Incheon, 402-751.
  • Jun-Young KWON Department of Biological Engineering, Inha University, Incheon, 402-751.
  • Boreum YUN Department of Biological Engineering, Inha University, Incheon, 402-751.
  • Ji-Yeon HAN Department of Biological Engineering, Inha University, Incheon, 402-751.
  • Sang-Min LIM Boryung Central Research Institute, Boryung Pharmaceutical Co. Ltd., Kyungki-Do.
  • Hahn-Sun JUNG Boryung Central Research Institute, Boryung Pharmaceutical Co. Ltd., Kyungki-Do.
  • Cheon-Ik PARK Boryung Central Research Institute, Boryung Pharmaceutical Co. Ltd., Kyungki-Do.
  • Seung-Hoon KANG Boryung Central Research Institute, Boryung Pharmaceutical Co. Ltd., Kyungki-Do.
  • Dong-Il KIM Department of Biological Engineering, Inha University, Incheon, 402-751.

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

      0개의 논문이 장바구니에 담겼습니다.